Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Sandler

Showing results (681-690 of 870) with videos related to

Pageof 87
Sort By:
European Urology|May 26, 2015
Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical ProstatectomyWilliam C Jackson, Matthew J Schipper, Skyler B Johnson, et al.
Communications in Psychopharmacology|January 1, 1978
Raised cerebrospinal fluid phenylacetic acid concentration: preliminary support for the phenylethylamine hypothesis of schizophrenia?M Sandler, C R Ruthven, B L Goodwin, et al.
International Journal of Radiation Oncology, Biology, Physics|February 16, 1999
Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric studyS W Lee, B A Fraass, L H Marsh, et al.
Radiation Oncology (London, England)|June 12, 2012
Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapyJeffrey Vainshtein, Eyad Abu-Isa, Karin B Olson, et al.
Urology|December 23, 2008
Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapyDonald S Kaufman, Kathryn A Winter, William U Shipley, et al.
International Journal of Radiation Oncology, Biology, Physics|May 5, 2009
Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boostSiavash Jabbari, Vivian K Weinberg, Katsuto Shinohara, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2009
Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation studyJeff M Michalski, Kyounghwa Bae, Mack Roach, et al.
Journal of Psychopharmacology (Oxford, England)|January 28, 2012
Clinical pharmacology of moclobemide, a new reversible monoamine oxidase inhibitorS J Warrington, P Turner, T G Mant, et al.
Seminars in Radiation Oncology|April 10, 1999
Optimization and clinical use of multisegment intensity-modulated radiation therapy for high-dose conformal therapyB A Fraass, M L Kessler, D L McShan, et al.
International Journal of Radiation Oncology, Biology, Physics|March 1, 1994
Results of primary and adjuvant CT-based 3-dimensional radiotherapy for malignant tumors of the paranasal sinusesW H Roa, M B Hazuka, H M Sandler, et al.
Pageof 87

Showing results (681-690 of 870) with videos related to

Sort By:
Pageof 87
European Urology|May 26, 2015
Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical ProstatectomyWilliam C Jackson, Matthew J Schipper, Skyler B Johnson, et al.
Communications in Psychopharmacology|January 1, 1978
Raised cerebrospinal fluid phenylacetic acid concentration: preliminary support for the phenylethylamine hypothesis of schizophrenia?M Sandler, C R Ruthven, B L Goodwin, et al.
International Journal of Radiation Oncology, Biology, Physics|February 16, 1999
Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric studyS W Lee, B A Fraass, L H Marsh, et al.
Radiation Oncology (London, England)|June 12, 2012
Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapyJeffrey Vainshtein, Eyad Abu-Isa, Karin B Olson, et al.
Urology|December 23, 2008
Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapyDonald S Kaufman, Kathryn A Winter, William U Shipley, et al.
International Journal of Radiation Oncology, Biology, Physics|May 5, 2009
Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boostSiavash Jabbari, Vivian K Weinberg, Katsuto Shinohara, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2009
Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation studyJeff M Michalski, Kyounghwa Bae, Mack Roach, et al.
Journal of Psychopharmacology (Oxford, England)|January 28, 2012
Clinical pharmacology of moclobemide, a new reversible monoamine oxidase inhibitorS J Warrington, P Turner, T G Mant, et al.
Seminars in Radiation Oncology|April 10, 1999
Optimization and clinical use of multisegment intensity-modulated radiation therapy for high-dose conformal therapyB A Fraass, M L Kessler, D L McShan, et al.
International Journal of Radiation Oncology, Biology, Physics|March 1, 1994
Results of primary and adjuvant CT-based 3-dimensional radiotherapy for malignant tumors of the paranasal sinusesW H Roa, M B Hazuka, H M Sandler, et al.
Pageof 87